A New Milestone in Robotic Cardiac Surgery: First Use of a Purpose-built Robotic Delivery System for Surgical Valve Implantation

• A robotic-assisted aortic valve replacement marked the first-ever use of a purposefully designed robotic delivery system for surgical valve implantation, introducing a technological advancement developed specifically for robotic surgery.

(USA) – Unlike conventional approaches, where valve deployment is performed manually by the bedside surgeon, this system is designed to interface directly with the robotic platform, enabling robot-assisted valve deployment.

The procedure combined robotic-assisted surgery with our Perceval Plus LANCELOT sutureless valve technology, allowing implantation through a minimal incision and enabling the robot to perform the valve release.

Dr. Michael E. Ibrahim, who performed the procedure in Philadelphia, commented:

“With its sutureless implantation, hemodynamic performance and long-term durability data, Perceval was a natural choice for robotic aortic valve replacement. Today, it becomes the only heart valve with a specifically robotic deployment mechanism. This is a landmark moment and ushers in an era of purpose designed tools which will unleash the potential of robotic cardiac surgery.”

This milestone builds on a growing body of innovation in cardiac surgery, where robotics and advanced technologies are reshaping what is possible in the operating room. In this evolving landscape, the integration of robotics with purpose-built surgical technologies represents a critical step forward: it refines how surgery is performed.

This advancement reflects our broader commitment to enabling the Surgeon of the Future: a highly skilled clinician supported by technologies specifically designed to enhance decision-making, precision, and procedural efficiency. By equipping surgeons with tools tailored to robotic workflows, the next generation of cardiac procedures can deliver both minimally invasive access and long-term clinical performance.

We would like to thank Dr. Michael E. Ibrahim and his team in Philadelphia for their collaboration and leadership in achieving this important first.

Christian Mazzi, CEO at Corcym added:

“This first use is more than a procedural milestone. It is a signal of what comes next: a new paradigm in cardiac surgery, enabled by robotics and purpose-designed solutions. By giving the robot the ability to control valve deployment, we are empowering the Surgeon of the Future, opening a new era in minimally invasive cardiac care.”

RelyON-R is not approved and not commercially available in any market.

About Corcym

Corcym is the only global medical device company dedicated to cardiac surgeons, providing the best solutions to help their patients fight structural heart disease. Founded on five decades of trusted partnerships with cardiac surgeons and a comprehensive portfolio of structural heart solutions. Corcym’s innovative technologies offer surgeons a wide range of repair and replacement options for both open-heart and minimally invasive cardiac surgery techniques. https://www.corcym.com/

Original source here.